Otezla gets another No from NICE

[jiml]

They haven't said yet Jim as far as I know but to quote the reason for a no for psoriatic arthritis I would say the reason is much the same.

Quote:

---

compared with TNF-alpha inhibitors, apremilast was the least clinically effective for treating psoriatic arthritis although some costs were saved by its use. Importantly, there was not enough robust evidence demonstrating that apremilast slows progression of the disease compared to TNF-alpha inhibitors.

Again I'll say what I said before there's no way to get robust evidence without having it out there being used ,